The verdict
Our read at a glance.
Whether a horse anabolic has any established human profile.
- The signal
- There is no human efficacy trial. The indexed literature is animal work - toxicological studies in rodents and livestock examining hepatic, renal, reproductive and cardiac effects of boldenone exposure - together with residue and metabolite analysis developed for doping control and food safety. Its endogenous occurrence in some animals is itself a live analytical problem, which is why so much of the published work is about distinguishing administration from natural presence.
- The unknown
- Everything about human exposure. No dose-response, no controlled safety data, and no characterisation of the erythrocytosis users describe, which would be the most clinically consequential effect if confirmed.
- Our read
- Judged as a medicine it has no file at all. Its mild reputation is an artefact of slow-onset kinetics rather than any demonstrated safety, and the one effect users consistently describe - rising haematocrit - is the one nobody has measured properly.
The mechanism
How it works.
Boldenone is testosterone with an additional double bond between carbons 1 and 2, the same modification that distinguishes methandienone but without the 17-alpha methyl group, so it is injectable rather than oral and is not hepatotoxic in the 17-alpha-alkylated sense. It binds the androgen receptor with moderate potency and is a substrate for aromatase, though it converts to oestradiol less readily than testosterone does. The undecylenate ester is very long, which is why concentrations rise and fall slowly, why effects are described as gradual, and why the axis stays suppressed and the compound stays detectable long after the last injection.
Safety & regulatory boundary
The consequential part.
Not approved for human use; licensed as a veterinary product. A Schedule III controlled substance in the United States. It aromatises, so oestrogenic effects occur, and it has a very long ester half-life with correspondingly prolonged detection and prolonged suppression. Reported increases in haematocrit are a thrombotic concern that has never been formally studied in humans. Prohibited in sport.
What's next
What we're watching.
Nothing in human development. Continued residue surveillance and any published human case series.
Context
Why this is discussed.
It has a reputation for steady gains with low side effects and for raising appetite, and it is one of the most common injectables in amateur use.
The evidence base
13 cited references.
Registered trials1
ClinicalTrials.gov · PHASE2 · COMPLETED · 2015-10-29
Indexed literature (PubMed)12
Piraccini BM et al. · G Ital Dermatol Venereol · 2014
Mendoza Sanabria SM et al. · Anal Methods · 2024
Kollerov VV et al. · J Fungi (Basel) · 2024
El-Shamarka ME et al. · J Biochem Mol Toxicol · 2022
Dirikolu L et al. · J Vet Pharmacol Ther · 2023
De Brabander HF et al. · Food Addit Contam · 2004
Viljanto M et al. · Drug Test Anal · 2024
Viljanto M et al. · Drug Test Anal · 2022
Mowaad NA et al. · Neurochem Res · 2023
El Deib MM et al. · Int Immunopharmacol · 2021
Viljanto M et al. · Drug Test Anal · 2020
Keep reading